Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

The tyrosine kinase inhibitor sunitinib is used as first‐line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed‐dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in res...

Descripción completa

Detalles Bibliográficos
Autores principales: Diekstra, MH, Fritsch, A, Kanefendt, F, Swen, JJ, Moes, DJAR, Sörgel, F, Kinzig, M, Stelzer, C, Schindele, D, Gauler, T, Hauser, S, Houtsma, D, Roessler, M, Moritz, B, Mross, K, Bergmann, L, Oosterwijk, E, Kiemeney, LA, Guchelaar, HJ, Jaehde, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613186/
https://www.ncbi.nlm.nih.gov/pubmed/28571114
http://dx.doi.org/10.1002/psp4.12210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613186/
https://www.ncbi.nlm.nih.gov/pubmed/28571114
http://dx.doi.org/10.1002/psp4.12210

Ejemplares similares